Rein Therapeutics Inc. (RNTX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Here's Why You Should Add RNTX Stock to Your Portfolio Now
Rein Therapeutics advances LTI-03 in IPF. RENEW enrollment tops 25%, with interim data expected in the fourth quarter of 2026.
All You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to Buy
Rein Therapeutics Inc. (RNTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Rein Therapeutics (NASDAQ:RNTX) Stock Price Up 1.6% – What’s Next?
Shares of Rein Therapeutics Inc. (NASDAQ: RNTX - Get Free Report) traded up 1.6% during trading on Friday. The stock traded as high as $1.3451 and last traded at $1.30. 44,298 shares changed hands during trading, a decline of 51% from the average session volume of 90,560 shares. The stock had previously closed at $1.28.
Rein Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JRP Jay R. Petschek Corsair Capital Management LP | 80,000 | $83,200 | $64,480 | -$18,720 | -22.5% |
| YA Yinka Akinsola Blue Trust Inc. | 20 | $35.4 | $15.55 | -$19.85 | -56.07% |
 Richard Slavik Newbridge Financial Services Group Inc. | 97 | $126.1 | $75.42 | -$50.68 | -40.19% |
 Tyler Glazier New Millennium Group LLC | 2,038 | $2,364.08 | $1,502.01 | -$862.07 | -36.47% |
 Hui Fai Tam Caitong International Asset Management Co. Ltd. | 1 | $1.33 | $0.78 | -$0.55 | -41.35% |
Rein Therapeutics Inc. (RNTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Rein Therapeutics Inc. ever had a stock split?
Rein Therapeutics Inc. Profile
| Pharmaceuticals Industry | Healthcare Sector | James Brian Windsor CEO | NASDAQ (CM) Exchange | 00887A204 CUSIP |
| US Country | 10 Employees | - Last Dividend | 11 Nov 2022 Last Split | - IPO Date |
Overview
Rein Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to innovating and commercializing a new class of therapeutics aimed at treating cancer and other serious diseases. The company is particularly focused on the development of its lead product candidate, ALRN-6924, which has the potential to transform the paradigm of cancer treatment. This innovative product is a cell-permeating peptide specifically designed to interrupt the interaction of p53 suppressors, MDM2 and MDMX, with the tumor suppressor protein p53. By reactivating tumor suppression in cancers that retain non-mutated or wild-type p53, the therapy holds promise for enhancing tumor regression and improving patient outcomes. Founded on August 6, 2001, by a team of experts including Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, Rein Therapeutics is headquartered in Austin, Texas.
Products and Services
- ALRN-6924:
This is the lead product candidate from Rein Therapeutics. ALRN-6924 is a novel cell-permeating peptide that targets the MDM2 and MDMX proteins, which inhibit the function of the p53 tumor suppressor. By disrupting these interactions, ALRN-6924 aims to reactivate p53 and restore its tumor suppressor activities in non-mutated p53 cancers, thereby providing a new treatment avenue for patients afflicted with such tumors.
